Neurocrine(US:NBIX)2022-01-24 16:35Company Vision and Purpose - The company's vision is understanding the brain to treat the body, relieving patient suffering, and taking responsibility beyond medicine[5] - The company's purpose is to relieve suffering for people with great needs, but few options[6] Commercial Products and Pipeline - Commercial products are fueling pipeline investment, focusing on neurology, neuroendocrinology, and psychiatry[7,9] - The company achieved approximately $1 billion in annual sales in 35 years[13] - The company has a strong financial position with approximately $13 billion in cash and investments as of September 30, 2021[13] - The company has 13 total mid- to late-stage programs[13] Pipeline Focus and Development - The company is tackling difficult and undertreated diseases in neuroscience, including Parkinson's Disease, Tardive Dyskinesia, and others[15,16] - Development programs are dominated by mid- and late-stage studies[56] - There are approximately 500000 undiagnosed and untreated patients in the US with TD[13] Upcoming Milestones - Significant milestones this year include valbenazine sNDA filing for Chorea in Huntington Disease and Phase 2 data for NBI-827104 in CSWS and Essential Tremor[59] - 2023 clinical activities & milestones include Crinecerfont registrational top-line data for CAH in adults and pediatrics, and valbenazine sNDA approval for Chorea in Huntington Disease[60]